A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

PHASE1TerminatedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2017

Study Completion Date

May 31, 2017

Conditions
Primary Liver CancerSCLCLymphomaMelanomaMultiple MyelomaRenal Cell CarcinomaNSCLC
Interventions
DRUG

MRX34

micro RNA therapy

Trial Locations (10)

75246

Texas Oncology Dallas, Dallas

75390

UT Southwestern Medical Center, Dallas

77030

MD Anderson Cancer Center, Houston

78229

Uthscsa/Ctrc, San Antonio

85258

Virginia G. Piper Cancer Center, Scottsdale

85259

Mayo Clinic Arizona, Scottsdale

03722

Severance Hospital, Yonsie University Health System, Seoul

110-744

Seoul National University Hospital, Seoul

135-710

Samsung Medical Center, Seoul

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Cancer Prevention Research Institute of Texas

OTHER

lead

Mirna Therapeutics, Inc.

INDUSTRY